IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045

Cho, N.H.; Shaw, Jonathan E.; Karuranga, Suvi; Huang, Yunbo; Fernandes, J; Ohlrogge, Anne Wiebke; Malanda, Belma

doi:10.1016/j.diabres.2018.02.023

Cited by 5,658 publications

(4,367 citation statements)

References 20 publications

Supporting

Mentioning

3,849

Contrasting

Unclassified

144

Order By: Relevance

“…Diabetes mellitus (DM) is a global health problem. It was estimated that in 2017, 425 million people were living with diabetes and by 2045, 629 million will become diabetic . In 2015, the direct and indirect global costs of DM were almost 2% of global gross domestic product, which equates to nearly 1.5 trillion American dollars .…”

Section: Introductionmentioning

confidence: 99%

Insulin resistance is improved in high‐fat fed mice by photobiomodulation therapy at 630 nm

Silva

Ferraresi

Almeida

et al. 2020

Journal of Biophotonics

View full text Add to dashboard Cite

Photobiomodulation therapy (PBMT) in the infrared spectrum exerts positive effects on glucose metabolism, but the use of PBMT at the red spectrum has not been assessed. Male Swiss albino mice were divided into low‐fat control and high‐fat diet (HFD) for 12 weeks and were treated with red (630 nm) PBMT or no treatment (Sham) during weeks 9 to 12. PBMT was delivered at 31.19 J/cm2, 60 J total dose per day for 20 days. In HFD‐fed mice, PBMT improved glucose tolerance, insulin resistance and fasting hyperinsulinemia. PBMT also reduced adiposity and inflammatory infiltrate in adipose tissue. Phosphorylation of Akt in epididymal adipose tissue and rectus femoralis muscle was improved by PBMT. In epididymal fat PBMT reversed the reduced phosphorylation of AS160 and the reduced Glut4 content. In addition, PBMT reversed the alterations caused by HFD in rectus femoralis muscle on proteins involved in mitochondrial dynamics and β‐oxidation. In conclusion, PBMT at red spectrum improved insulin resistance and glucose metabolism in HFD‐fed mice.

show abstract

Section: Introductionmentioning

confidence: 99%

Insulin resistance is improved in high‐fat fed mice by photobiomodulation therapy at 630 nm

Silva

Ferraresi

Almeida

et al. 2020

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…According to the data obtained from the International Diabetes Federation and related studies, more than 400 million people (age 18-99 years) are diagnosed with diabetes worldwide, and more than 90% of them suffer from type 2 diabetes (T2D) (Cho et al, 2018;Zheng et al, 2018). Diabetes is characterized by hyperglycemia, polyuria, polydipsia, and polyphagia, and could be divided into type 1 and type 2, according to different pathogeneses.…”

Section: Introductionmentioning

confidence: 99%

Regulation of insulin resistance by targeting the insulin‐like growth factor 1 receptor with microRNA‐122‐5p in hepatic cells

Dong

Hou

Liu

et al. 2019

Cell Biology International

View full text Add to dashboard Cite

Insulin resistance (IR) is a common etiology of type 2 diabetes (T2D) defined by a state of decreased reactivity to insulin in multiple organs, such as the liver. This study aims to investigate how microRNA-122-5p (miR-122) regulates the hepatic IR in vitro. We first found that the miR-122 level was upregulated in the liver of rats fed with a high-fat diet and injected with streptozotocin (T2D rats), while the expression level of insulin-like growth factor 1 receptor (IGF-1R), a potential target of miR-122, was downregulated in the diabetic liver. In vitro, glucosamine-induced IR was introduced in HepG2 hepatic cells, and the levels of miR-122 and IGF-1R were further assessed. An increase of miR-122 level and a decrease of IGF-IR level were observed in IR hepatic cells, which was the same as that in the diabetic liver. Results of the luciferase reporter assay validated IGF-1R as a direct target of miR-122. Moreover, in IR HepG2 cells, antagonizing miR-122 with its specific inhibitor enhanced glucose uptake and suppressed the expression of glucose 6-phosphatase and phosphoenolpyruvate carboxykinase, two key enzymes in regulating gluconeogenesis. Such alterations induced by the miR-122 inhibitor in IR hepatic cells were impaired when IGF-1R was simultaneously knocked down. In addition, the PI3K/Akt pathway was deactivated in IR cells, and then reactivated with miR-122 inhibitor transfection. In conclusion, our study demonstrates that miR-122 is able to regulate IR in hepatic cells by targeting IGF-1R.

show abstract

“…1,2 Clinical epidemiologists have revealed that T2DM is chiefly rising in the developing countries. Instead, they have rose from over 2 million in 2004 to nearly 3.5 million in 2015 and have become a critical public health challenge.…”

Section: Introductionmentioning

confidence: 99%

Clinical and radiographic indices around narrow diameter implants placed in different glycemic‐level patients

Alsahhaf

Alshiddi

Alshagroud

et al. 2019

Clin Implant Dent Rel Res

View full text Add to dashboard Cite

Background: Studies assessing peri-implant clinical and marginal bone resorption (MBR) around narrow diameter implants (NDIs) placed in different glycemic levels are uninvestigated. Objective: The present 3-year retrospective follow-up investigation was designed to explore clinical and radiographic status of NDIs placed in individuals with different glycemic control levels. Materials and Methods: Patients with serum hemoglobin A1c (HbA1c) levels ≥6.5% (Group-1), 5.7%-6.4% (Group-2), and 4.0%-5.0% (Group-3) were included. Clinical indices evaluating bleeding on probing (BOP), plaque scores (PI), peri-implant probing depth (PD), and MBR were recorded around NDIs at 1-, 2-, and 3-year follow-up. Serum HbA1c test was carried out for all patients to assess the profile of glycosylated hemoglobin at 1 and 3 years of follow-up. Results: A significant reduction in mean HbA1c levels from year 1 to year 3 followup period was seen in Group-1 only. PI varied from 0.40 in Group 1 at 2 year and 0.42 at 3-year follow-up to 0.18 at 2-year (P = 0.032) and 0.17 at 3-year (P = 0.018) follow-up, respectively. Greater BOP was noted in Group 1 (0.53) as compared with Group 2 (0.42) and Group 3 (0.21) (P = 0.048) at 3-year follow-up. PD after 3 year ranged from 2.04 mm in Group 3 to 2.32 mm in Group 1 that showed statistically significant difference (P = 0.037). No statistical significant differences were observed in MBR at any time point between the groups. Conclusion: The results of this short-term follow-up study indicate that NDIs show clinical and radiographic stability, provided oral cleanliness and glycemic levels are relatively maintained. Further long-term clinical studies are needed to evaluate implant stability over the period along with controlled glycemic status. K E Y W O R D S crestal bone levels, hyperglycemia, narrow implants, radiographs

show abstract

IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045

Abstract: The new estimates of diabetes prevalence, deaths attributable to diabetes and healthcare expenditure due to diabetes present a large social, financial and health system burden across the world.

Cited by 5,658 publications

References 20 publications

Insulin resistance is improved in high‐fat fed mice by photobiomodulation therapy at 630 nm

Insulin resistance is improved in high‐fat fed mice by photobiomodulation therapy at 630 nm

Regulation of insulin resistance by targeting the insulin‐like growth factor 1 receptor with microRNA‐122‐5p in hepatic cells

Clinical and radiographic indices around narrow diameter implants placed in different glycemic‐level patients

Contact Info

Product

Resources

About